13 — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00- HK$19.44bn
- HK$9.50bn
- $548.51m
Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
UK Stocks-Factors to watch on September 29 (updated)
Submission of US NDA for ORPATHYS® plus TAGRISSO
UK Stocks-Factors to watch on September 29
China's HUTCHMED climbs as AstraZeneca applies for US cancer drug approval
Brief: Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination (updated)
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
Hutchmed Initiates Global Trial Of Hmpl: A830
Hutchmed Climbs After On Initiating Hmpl: A830 global trial in solid tumors
Brief: Hutchmed (China) Initiates Global Phase A Trial Of HMPL-A830 In Advanced Solid Tumors
Data to be Presented at ESMO 2026
UK Stocks-Factors to watch on September 3 (updated)
Hutchmed Licenses Kras: EGFR-Antibody to GSK
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug (updated)